Daniel Heindel, PhD, is a seasoned researcher with extensive experience in the field of biochemistry and infectious diseases. At the Icahn School of Medicine at Mount Sinai, from September 2020 to September 2023, Daniel conducted pioneering research on HIV-1 and bacterial protein interactions, notably employing high-throughput lectin microarrays to investigate O-linked glycans on HIV-1 viral particles. Earlier, as a PhD Candidate in Chemistry at New York University from 2013 to 2020, Daniel led innovative studies on host glycomic changes due to infections. Daniel also served as a Junior Research Associate at New York University from September 2012 to September 2013. Currently, as a Principal Scientist at Pfizer since September 2023, Daniel plays a key role in the RSV neutralization assay team, providing critical bio-functional data for vaccine clinical trials and managing project timelines effectively. Daniel holds a Bachelor of Science in Chemistry from New York University, obtained in 2011.
This person is not in any teams
This person is not in any offices